London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
You will only have one login account. Registering with multiple accounts is not allowed. Any user found to have more than one account on this site will have all, and any future accounts suspended permanently.
Your email and password must only be used by you. If a post is made under your account, it will be considered that it was posted by yourself.
Your account nickname must not be the same, or contain, listed company names or board members' names.
While debating and discussion is fine, we will not tolerate; rudeness, swearing, insulting posts, personal attacks, or posts which are invasive of another's privacy.
You will not;
discuss illegal or criminal activities.
post any confidential or price sensitive information or that is not public knowledge.
post misleading or false statements regarding the share price and performance. Such posts are deemed as market abuse, and may be reported to the appropriate authorities.
post any private communication, or part thereof, from any other person, including from a member of the board of directors of a listed company. Such posts cannot be verified as true and could be deemed to be misleading.
post any personal details (e.g. email address or phone number).
post live price or level 2 updates.
publish content that is not your original work, or infringes the copyright or other rights of any third party.
post non-constructive, meaningless, one word (or short) non-sense posts.
post links to, or otherwise publish any content containing any form of advertising, promotion for goods and services, spam, or other unsolicited communication.
post any affiliate or referral links, or post anything asking for a referral.
post or otherwise publish any content unrelated to the board or the board's topic.
re-post premium share chat posts on regular share chat.
restrict or inhibit any other user from using the boards.
impersonate any person or entity, including any of our employees or representatives.
post or transmit any content that contains software viruses, files or code designed to interrupt, destroy or limit the functionality of this website or any computer software or equipment.
If you are going to post non-English, please also post an English translation of your post.
If you are going to post non-English, please also post an English translation of your post.
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium and Verified Members
Premium Members are members that have a premium subscription with London South East and have access to Premium Chat. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Yes, I was expecting something more material as well. The information was largely already known info and the only additional information was on some further preclinical trials carried out on mice. Still can't figure out why this would warrant a suspension on ASX. Those guys must be scratching their heads as well.
These findings support the understanding of the mechanism of action of ArtemiCTM and additional potential application of the study product. This data will be used in the design of future clinical trials of the Company in different indications. Following the successful Phase II clinical trial results (refer ASX release 15 December 2020), ArtemiCTM demonstrated efficacy in COVID-19 infected patients. Patients in the treatment group fully clinically recovered within 15 days of follow up. The ArtemiCTM results delivered a full safety and efficacy profile, demonstrating its ability to improve and expedite the clinical recovery in mild and moderate COVID-19 patients. MGC Pharma continues the preclinical development on ArtemiC™ while progressing with the clinical development program for CimetrATM as an Investigational Medicinal Product (IMP) to demonstrate the full efficacy and pharmacokinetic profile of the treatment in a Phase III clinical trial (submitted on the clinical drug development program of IMP version of ArtemiCTM). Importantly once the inflammation process associated with COVID-19 is under control, the effects of ‘long COVID’, the post COVID syndrome should be minimised. MGC Pharma will initiate a sub-trial in combination with the upcoming Phase III clinical trial to prove this hypothesis. As per the FDA recommendations and based on the last findings, MGC Pharma will initiate a sub-trial for patients who complete the Phase III trial, observing them for an additional three (3) months to document the post COVID syndrome symptoms both in the treatment and placebo groups. Roby Zomer, Co-founder and Managing Director of MGC Pharma, commented: “The findings from the phase II clinical trials which are supported by the completed preclinical trial results, continue to demonstrate the effectiveness of ArtemiC™ in treating patients with different variants of COVID-19. “We are now looking to get ArtemiCTM into more territories as a supplement and herbal health product following these findings.”
Key Highlights: • ArtemiCTM Rescue (ArtemiC™) designed with the scientific aim to target viral infections with inflammatory complications, and was successfully evaluated on COVID-19 infected patients in a double-blind, placebo-controlled Phase II clinical trial. • Preclinical and Clinical results to date have demonstrated ArtemiCTM‘s mechanism of action as an anti-inflammatory and immunomodulatory agent effective in the prevention of increased cytokine production, found in different variants and mutations of COVID-19; the forerunner of cytokine storm – believed to be the main reason for mortality in severe COVID-19 patients. • Preclinical trial work, completed by MGC Pharma, showed the ability of ArtemiCTM to decrease the markers of inflammation (IFN-g, IL-1a and TNF-a), in the bronchoalveolar lavage fluid (BALF) of mice in the animal model of cytokine storm related to COVID-19 and in human trials to control the inflammation process in COVID-19 patients. • Successful ArtemiCTM Phase II clinical trials performed in India and Israel have demonstrated the capacity of ArtemiCTM to improve and expedite the clinical recovery in mild to moderate patients suffering from COVID-19. MGC Pharmaceuticals Ltd (ASX, LSE: MXC, ‘MGC Pharma’ or ‘the Company’), a European based bio-pharma company specialising in the production and development of phytocannabinoid- derived medicines, is pleased to announce further results from the Phase II clinical and preclinical studies on ArtemiCTM, evaluating the efficacy on anti-inflammatory agents for increased cytokine, which is found in different variants and mutations of COVID-19 and post COVID-19 syndrome. The mechanism of action of ArtemiCTM is focused on the anti-inflammatory effect and prevention of cytokine storm – believed to be the main reason for mortality in COVID-19 patients. Preclinical and clinical results to date support ArtemiCTM being effective for addressing cytokine over production in all tested COVID patients. On 15 December 2020, the Company released to the ASX results from its Phase II clinical trial results from patients in India and Israel. The preclinical trial “Evaluation the Efficacy of ArtemicTM Treatment in ARDS Model in Mice” was performed in the SIA preclinical Lab (GLP certified) in Israel. The ARDC model is the recommended preclinical animal model for the cytokine storm for the prediction of the human model of COVID-19 patients. The level of the pro-inflammatory markers was measured in blood and BALF (bronchoalveolar lavage fluid) of the mice going through the cytokine storm. The results demonstrated decreased blood and BALF cytokine levels in the study arm treated by ArtemicTM. Refer to Annexure A for additional information on the preclinical study and summary of results. These findings support the understanding of the mechanism of action of ArtemiCTM and additional potential application of the study product. This data will be used in t